Application value of tirofiban hydrochloride during percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction

Han Gongzhu

doi:10.3760/cma.j.issn.1673-4777.2017.08.004

Abstract：Objective To explore the application value of tirofiban hydrochloride during percutaneous coronary intervention(PCI) for acute ST-segment elevation myocardial infarction (STEMI).Methods A total of 72 patients with acute STEMI undergoing PCI from January 2014 to June 2015 in Jiaozhou Central Hospital of Qingdao in Shandong Province were randomly divided into observation group and control group,with 36 cases in each group.The observation group used tirofiban hydrochloride in PCI and the control group used 0.9％ sodium chloride injection.Infarction related artery(IRA) blood flow,cardiac function indexes and the incidence of postoperative adverse cardiovascular events were analyzed.Results There was no significant difference of IRA blood flow between groups before PCI (P ＞ 0.05);the IRA blood flow in observation group after operation was significantly improved than that in control group (P ＜ 0.05).On 30,60 d after PCI,left ventricular end systolic/ diastolic diameters in observation group were significantly lower and left ventricular ejection fraction was significantly higher than those in control group [postoperative 30 d:(32 ± 4) mm vs (38 ± 4) mm,(43 ± 5) mm vs (52 ± 4)mm,(55±9)％ vs (52±9)％;postoperative 60 d:(32±4)mmvs (39±4)mm,(45±6)mmvs (50± 5)mm,(56 ± 10)％ vs (51 ± 10)％] (P ＜0.05).The 3-month incidence of adverse cardiovascular events in observation group was significantly lower than that in control group [8.3％ (3/36) vs 30.6％ (11/36)] (P ＜ 0.05).Conclusion Application of tirofiban hydrochloride in PCI treating STEMI can effectively improve coronary blood flow and cardiac function and reduce the incidence of adverse events.